Physician profile
Michelle Silver
$1,827.79
in general payments reported to CMS, 2019-2025
14 companies · $696 in 2025
The $696 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $226 · 2023: $501 · 2024: $404 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $246.68 | 2023-2024 | Venaseal, Compia Mri Quad Crt-D Surescan |
| Genzyme Corporation | $237.05 | 2024-2025 | |
| Genentech USA, INC. | $130.79 | 2022 | |
| Astellas Pharma US INC | $123.99 | 2025 | Vyloy |
| Xeris Pharmaceuticals, INC. | $122.40 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $121.28 | 2023 | |
| Neurocrine Biosciences, INC. | $120.87 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $120.19 | 2024 | Uptravi, Opsumit |
| Pulmonx Corporation | $117.73 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Merz North America, INC. | $107.78 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $105.36 | 2025 | |
| Horizon Therapeutics Plc | $95.63 | 2022 | |
| Neurelis, INC. | $93.52 | 2024 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.52 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.